

# Isabelle Bence-Bruckler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2618549/publications.pdf>

Version: 2024-02-01

35  
papers

998  
citations

932766

10  
h-index

610482

24  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1864  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. <i>Transplantation</i> , 2022, 106, 562-574.	0.5	7
2	Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience. <i>Blood</i> , 2021, 138, 2525-2525.	0.6	2
3	The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia. <i>Leukemia Research</i> , 2020, 88, 106285.	0.4	0
4	Whole brain radiotherapy improves survival outcomes in primary CNS lymphoma patients ineligible for systemic therapy. <i>Supportive Care in Cancer</i> , 2020, 28, 5363-5369.	1.0	8
5	Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study. <i>Blood</i> , 2020, 136, 16-16.	0.6	2
6	BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure. <i>Blood</i> , 2020, 136, 40-41.	0.6	1
7	Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. <i>Blood</i> , 2020, 136, 54-55.	0.6	0
8	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	0.6	89
9	Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study. <i>Blood</i> , 2019, 134, 3236-3236.	0.6	3
10	BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission. <i>Blood</i> , 2019, 134, 2933-2933.	0.6	1
11	Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt. <i>Blood</i> , 2019, 134, 1653-1653.	0.6	0
12	The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up. <i>Blood</i> , 2019, 134, 1644-1644.	0.6	1
13	Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial. <i>Blood</i> , 2018, 132, 787-787.	0.6	17
14	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. <i>Leukemia and Lymphoma</i> , 2017, 58, 2824-2832.	0.6	15
15	Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. <i>JAMA Neurology</i> , 2016, 73, 652.	4.5	71
16	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
17	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. <i>Lancet, The</i> , 2016, 388, 576-585.	6.3	296
18	ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2016, 387, 770-778.	6.3	389

#	ARTICLE	IF	CITATIONS
19	Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. <i>Blood</i> , 2016, 128, 1922-1922.	0.6	11
20	Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure. <i>Blood</i> , 2016, 128, 1907-1907.	0.6	0
21	Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5782-5782.	0.6	1
22	Outcomes of both abbreviated hyper- $\epsilon$ -CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review. <i>Cancer Medicine</i> , 2015, 4, 1817-1827.	1.3	2
23	Disseminated histoplasmosis associated with acquired hemophagocytic lymphohistiocytosis. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 195-196.	0.2	5
24	A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 303-313.	0.2	1
25	Ibrutinib Vs Tamsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2015, 126, 469-469.	0.6	3
26	Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review. <i>Blood</i> , 2015, 126, 5606-5606.	0.6	0
27	Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Tamsirolimus. <i>Blood</i> , 2015, 126, 1542-1542.	0.6	0
28	Autologous Stem Cell Transplantation for Stiff Person Syndrome. <i>JAMA Neurology</i> , 2014, 71, 1296.	4.5	29
29	Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience. <i>Blood</i> , 2014, 124, 3996-3996.	0.6	16
30	Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure. <i>Blood</i> , 2014, 124, 4554-4554.	0.6	0
31	Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). <i>ClinicalTrials.Gov Identifier: NCT00530179</i> . <i>Blood</i> , 2011, 118, 500-500.	0.6	0
32	A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase. <i>Blood</i> , 2011, 118, 4437-4437.	0.6	0
33	Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant. <i>Blood</i> , 2010, 116, 3567-3567.	0.6	2
34	A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2010, 116, 428-428.	0.6	9
35	Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH). <i>Blood</i> , 2010, 116, 1390-1390.	0.6	0